학술논문
Occult Autoimmune Background for Epilepsy-The Preliminary Study on Antibodies Against Neuronal Surface Antigens.
Document Type
Academic Journal
Author
Dziadkowiak E; Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.; Moreira H; Department of Basic Medical Sciences, Wroclaw Medical University, Wroclaw, Poland.; Buska-Mach K; Euroimmun Poland, Wroclaw, Poland.; Szmyrka M; Department of Rheumatology, Wroclaw Medical University, Wroclaw, Poland.; Budrewicz S; Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.; Barg E; Department of Basic Medical Sciences, Wroclaw Medical University, Wroclaw, Poland.; Janik M; Euroimmun Poland, Wroclaw, Poland.; Pokryszko-Dragan A; Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
Source
Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1664-2295
Abstract
Objective: The objective of the study was to determine the incidence of antibodies against neuronal surface antigens (NSA-ab) in patients with different types of epilepsy, in comparison with the subjects diagnosed with immune-mediated disorders. Methods: Forty patients with drug-resistant epilepsy (DRE) of unknown origin, 16 with post-stroke epilepsy, and 23 with systemic autoimmune disorders (SAD) with CNS involvement were included. NSA-ab were sought in serum using indirect immunofluorescence method. Relationships were analyzed between presence of NSA-ab and clinical presentation. Results: NSA-ab was detected in the sera from five patients: anti-DPPX in one patient, anti-AMPAR1/R2 in two, anti-LGI1 in one and, in one case, both anti-CASPR2 and DPPX IgG. Out of these five patients, three represented the SAD subgroup and two the DRE subgroup. None of the patients with post-stroke epilepsy was positive for NSA-ab. Significance: Autoimmune etiology is worth considering in patients with drug-resistant epilepsy of unknown origin. The presence of NSA-ab in patients with systemic autoimmune disorders may be caused by unspecifically enhanced autoimmune reactivity. NSA-ab seem not to be related to epilepsy resulting from ischemic brain injury.
Competing Interests: KB-M and MJ was employed by company Euroimmun Poland. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Dziadkowiak, Moreira, Buska-Mach, Szmyrka, Budrewicz, Barg, Janik and Pokryszko-Dragan.)
Competing Interests: KB-M and MJ was employed by company Euroimmun Poland. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Dziadkowiak, Moreira, Buska-Mach, Szmyrka, Budrewicz, Barg, Janik and Pokryszko-Dragan.)